Reimbursement Dispute Between Novitas And iRhythm Hits An Impasse
Local Medicare carrier Novitas raised its reimbursement rates for continuous cardiac monitoring, but iRhythm has concluded the rates are still too low and is preparing to discontinue serving this Medicare segment.
You may also be interested in...
The company provided another update on its ongoing efforts to secure adequate Medicare reimbursement for long-term continuous cardiac monitoring.
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
Local Medicare carrier Novitas met with monitoring companies to discuss rates for long-term ECG monitoring, but no final decision on recently proposed rate cuts has been reached, iRhythm reported.